Table 5.
Univariate analysis of hazards ratios for OS and DFS by clinical characteristics and MetS status.
| Variable | OS | DFS | ||||
|---|---|---|---|---|---|---|
| HR | CI (95%) | P | HR | CI (95%) | P | |
| Age(years) | ||||||
| ≤49 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| >49 | 1.509 | 0.863-2.638 | 0.149 | 1.355 | 0.838-2.190 | 0.216 |
| Menopause | ||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Yes | 2.316 | 1.315-4.079 | 0.004 | 1.792 | 1.108-2.898 | 0.017 |
| Number of births | ||||||
| 0 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| 1 | 1.213 | 0.470-3.126 | 0.690 | 1.255 | 0.564-2.794 | 0.578 |
| 2 | 1.629 | 0.574-4.627 | 0.359 | 1.507 | 0.614-3.697 | 0.370 |
| >2 | 1.299 | 0.310-5.436 | 0.720 | 0.912 | 0.236-3.528 | 0.894 |
| T Stage | ||||||
| cT1+cT2 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| cT3+cT4 | 1.301 | 0.691-2.448 | 0.415 | 1.182 | 0.674-2.073 | 0.560 |
| N Stage | ||||||
| N0 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| N1+N2+N3 | 2.786 | 0.385-20.181 | 0.311 | 0.615 | 0.247-1.529 | 0.296 |
| Hormone receptors | ||||||
| ER+/PR+ | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| ER+/PR- | 2.107 | 0.978-4.540 | 0.057 | 1.735 | 0.906-3.324 | 0.097 |
| ER-/PR- | 1.430 | 0.755-2.707 | 0.272 | 0.971 | 0.564-1.672 | 0.915 |
| HER2 | ||||||
| Negative | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Positive | 1.478 | 0.845-2.583 | 0.171 | 1.102 | 0.672-1.808 | 0.701 |
| Ki67(%) | ||||||
| ≤14 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| >14 | 1.334 | 0.683-2.605 | 0.399 | 1.318 | 0.742-2.341 | 0.346 |
| p53 | ||||||
| Negative | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Positive | 1.409 | 0.809-2.456 | 0.226 | 1.194 | 0.737-1.932 | 0.472 |
| Subtype | ||||||
| Luminal A | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Luminal B | 2.591 | 0.614-10.946 | 0.195 | 2.708 | 0.741-5.831 | 0.165 |
| HER2-E | 2.408 | 0.534-10.868 | 0.253 | 1.363 | 0.439-4.225 | 0.592 |
| TNBC | 3.118 | 0.698-13.933 | 0.137 | 1.868 | 0.615-5.676 | 0.270 |
| Endocrine therapy | ||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Yes | 0.818 | 0.462-1.448 | 0.491 | 1.345 | 0.833-2.172 | 0.225 |
| Radiation therapy | ||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Yes | 1.081 | 0.616-1.896 | 0.786 | 1.012 | 0.625-1.638 | 0.961 |
| MetS status | ||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Yes | 2.463 | 1.391-4.363 | 0.002 | 2.213 | 1.336-3.668 | 0.002 |
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HER2-E, HER2-enriched; TNBC, triple negative breast cancer; MetS, metabolic syndrome.